Romiplostim for treatment of thrombocytopenia in dogs: A retrospective assessment and clinical outcomes.

Autor: Ryu MO; Laboratory of Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Science and Research Institute for Veterinary Science, Seoul National University, Seoul 08826, Republic of Korea., Kim JK; Haemaru Companion Animal Medical Foundation, Seongnam, Republic of Korea., An JH; Department of Veterinary Emergency and Critical Care Medicine and Institute of Veterinary Science, College of Veterinary Medicine, Kangwon National University, Chuncheon-si, Republic of Korea., Seo KW; Laboratory of Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Science and Research Institute for Veterinary Science, Seoul National University, Seoul 08826, Republic of Korea., Oh YI; Department of Veterinary Internal Medicine, College of Veterinary Medicine & Institute for Veterinary Biomedical Science, Kyungpook National University, Daehakro 80, Daegu, Republic of Korea., Youn HY; Laboratory of Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Science and Research Institute for Veterinary Science, Seoul National University, Seoul 08826, Republic of Korea.
Jazyk: angličtina
Zdroj: Journal of veterinary internal medicine [J Vet Intern Med] 2024 Jul-Aug; Vol. 38 (4), pp. 2158-2164. Date of Electronic Publication: 2024 Jun 22.
DOI: 10.1111/jvim.17131
Abstrakt: Background: Romiplostim, a thrombopoietin analog, is commonly used to treat immune-mediated thrombocytopenia (ITP) in humans, but its use in dogs remains limited.
Objectives: Evaluate the effects and adverse events of romiplostim administration in dogs with thrombocytopenia caused by various underlying diseases.
Animals: Forty-two client-owned dogs with naturally occurring thrombocytopenia at 2 referral animal hospitals.
Methods: Retrospective, multi-institutional analysis to evaluate the outcomes of romiplostim treatment in dogs.
Results: Among the dogs treated with romiplostim, 27 experienced an increase in platelet count and 26 maintained a platelet count within the reference range. Platelet count improvement was observed in various conditions: primary ITP (90%, n = 18/20), pancytopenia of unknown etiology (42.9%, n = 3/7), chemotherapy-induced thrombocytopenia (50%, n = 3/6), babesiosis (100%, n = 1/1), radiotherapy-induced thrombocytopenia (0%, n = 0/1), and disseminated intravascular coagulopathy (33.3%, n = 2/6). The median time for platelet recovery (>50 000/μL) after romiplostim administration was 4 days, and the median time for platelet count normalization was 7 days. Median hospitalization time for the improvement group (I) was 5 days. The survival-to-discharge rates were 85%, 40%, and 28.6% for dogs with primary ITP, secondary thrombocytopenia, and thrombocytopenia of unknown etiology, respectively.
Conclusions and Clinical Importance: Romiplostim is a well-tolerated and promising treatment for primary ITP in dogs, suggesting its potential as a valuable therapeutic option for dogs with thrombocytopenia caused by various underlying conditions. These findings emphasize the need for further research to optimize romiplostim dosing and understand its role in treating secondary thrombocytopenia and pancytopenia of unknown etiology.
(© 2024 The Author(s). Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.)
Databáze: MEDLINE
Externí odkaz: